Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Receivables for 15 consecutive years, with $39.1 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables fell 51.17% year-over-year to $39.1 million; the TTM value through Mar 2026 reached $39.1 million, down 51.17%, while the annual FY2025 figure was $63.9 million, 18.36% up from the prior year.
  • Receivables hit $39.1 million in Q1 2026 for Corcept Therapeutics, down from $63.9 million in the prior quarter.
  • Across five years, Receivables topped out at $80.0 million in Q1 2025 and bottomed at $28.2 million in Q1 2022.
  • Average Receivables over 5 years is $51.7 million, with a median of $48.6 million recorded in 2023.
  • Year-over-year, Receivables surged 65.22% in 2023 and then crashed 51.17% in 2026.
  • Corcept Therapeutics' Receivables stood at $45.1 million in 2022, then decreased by 4.96% to $42.8 million in 2023, then soared by 35.62% to $58.1 million in 2024, then increased by 10.0% to $63.9 million in 2025, then crashed by 38.84% to $39.1 million in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $39.1 million, $63.9 million, and $73.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.